Liposomal Delivery of Peptides and Proteins

References

• Storm G., Wilms H. P., Crommelin D. J. A. Liposomes andbiotherapeutics. Biotherapy 1991; 3: 25–42
   PubMedGoogle Scholar
• Crommelin D. J. A., Storm G. Targeting of peptide and protein drugs. Eur. J. Pharm. Sci. 1994; 2: 17–18
   Google Scholar
• Crommelin D. J. A., Schreier H. Liposomes. Colloidal drug delivery systems, J. Kreuter. Marcel Dekker, Inc. 1994; 73–190
   Google Scholar
• Stormv G., Oussoren C., Peeters P. A. M., Barenholz Y. Tolerability of liposomes in vivo. Liposome Technology, 2nd Edition, G. Gregoriadis. CRC Press, Inc., Boca Raton 1993; Vol. Ill: 345–383
   Google Scholar
• Gregoriadis G. Liposome Technology, Vols. Mil, 2nd Edition. CRC Press, Inc., Boca Raton 1993
   Google Scholar
• Barenholz Y., Crommelin D. J. A. Liposomes as pharmaceutical dosage forms. Encyclopedia of Pharmaceutical Technology, J. Swarbrick, J. C. Boylan. Marcel Dekker, Inc., NY 1994; Vol. 9: 1–39
   Google Scholar
• Woodle M. C., Lasic D. D. Sterically stabilized liposomes. Biochim. Biophys. Acta 1992; 1113: 171–199
   PubMed Web of Science ®Google Scholar
• Allen T. M. The use of glycolipids and hydrophilic polymers in avoiding rapid uptake of liposomes by the mononuclear phagocyte system. Adv. DrugDeliv. Rev. 1994; 13: 285–309
   Web of Science ®Google Scholar
• Storm G., Belliot S., Daemen T., Lasic D. D. Surface modification of colloidal drug carriers for minimizing fast uptake by the mononuclear phagocyte system. Adv. Drug Deliv. Rev., in press
   Google Scholar
• Woodle M. C., Storm G., Newman M. S., Jekot J., Collins L. R., Martin F. J., Szoka F. C. Prolonged systemic delivery of peptide drugs by long circulating liposomes: illustration with vasopressin in the Brattleboro rat. Pharm. Res. 1992; 9: 260–265
   PubMed Web of Science ®Google Scholar
• Winkelhake J. L., Gauny G. S. Human recombinant interleukin-2 as an experimental therapeutic. Pharmacol. Rev. 1990; 42: 1–28
   PubMedGoogle Scholar
• Whittington R., Faulds D. Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer. Drugs 1993; 46: 446–514
   PubMed Web of Science ®Google Scholar
• Bergers J. J., Den Otter W., Dullens H. F. J., Kerkvliet C. T. M., Crommelin D. J. A. Interleukin-2-containing liposomes: interaction of interleukin-2 with liposomal bilayers and preliminary studies on application in cancer vaccines. Pharm. Res. 1993; 10: 1715–1721
   PubMed Web of Science ®Google Scholar
• Bergers J. J., Den Otter W., Crommelin D. J. A. Vesicles for tumour-associated antigen presentation to induce protective immunity: preparation, characterization and enhancement of the immune response by immunomodulators. J. Contr. Release 1994; 29: 317–327
   Web of Science ®Google Scholar
• Zimmerman R. J., Aukerman S. L., Katre N. V., Winkelhake J. L., Young J JS. Schedule dependency of the antitumor activity and toxicity of polyethylene glycol-modified interleukin-2 in murine tumor models. Cancer Res. 1989; 49: 6521–6528
   PubMed Web of Science ®Google Scholar
• Rutten V. P. M. G., Klein W. R., De Jong W. A. C., Misdorp W., Den Otter W., Sieerenberg P. A., De Jong W. H., Ruitenberg E. J. Local interleukin-2 therapy in bovine ocular squamous cell carcinoma. Cancer Immunol. Immunother. 1989; 30: 165–169
   PubMedGoogle Scholar
• Maas R. A., Dullens H. F. J., De Jong W. H., Den Otter W. Immunotherapy of mice with a large burden of disseminated lymphoma with low-dose interleukin 2. Cancer Res. 1989; 49: 7037–7040
   PubMed Web of Science ®Google Scholar
• Cortesina G., De Stefani A., Giovarelli M., Barioglio M. G., Cavallo G. P., Jemma C., Forni G. Treatment of recurrent squamous cellcarcinoma of the head and neck with low doses of interleukin 2 injected perilymphatically. Cancer 1988; 62: 2482–2485
   PubMed Web of Science ®Google Scholar
• Yoshida S., Tanaka R., Takai N., Ono K. Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumors. Cancer Res. 1988; 48: 5011–5016
   PubMed Web of Science ®Google Scholar
• Gaffney P. J. Tissue plasminogen activator for thrombolytic therapy: expectation versus reality. J. Royal Soc. Med. 1992; 85: 692–698
   PubMed Web of Science ®Google Scholar
• Owen J., Friedman K. D., Grossman B. A., Wilkins C, Berke A. D., Powers E. R. Thrombolytic therapy with tissue plasminogen activator of streptokinase induces transient thrombin activity. Blood 1988; 72: 616–620
   PubMedGoogle Scholar
• Seitz R., Pelzer H., Immel A., Egbring R. Prothrombin activation by dirombolytic agents. Fibrinolysis 1993; 7: 109–115
   Google Scholar
• Heeremans J. L. M., Kraaijenga J. J., Los P., Kluft C., Crommelin D. J. A. Development of a procedure for coupling the homing device glu-plasminogen to liposomes. Biochim. Biophys. Acta 1992; 1117: 258–264
   PubMed Web of Science ®Google Scholar
• Wright S., Huang L. Antibody-directed liposomes as drug-delivery vehicles. Adv. Drug Deliv. Rev. 1989; 3: 343–389
   Google Scholar
• Storm G., Peeters P. A. M., Nassander U. K., Crommelin D. J. A. Drug targeting with immunoliposomes. Trends in drug research, Pharmacochemistry Library, H. Timmerman. Elsevier, Amsterdam/Oxford/New York/Tokyo 1990; Vol. 13: 333–349
   Google Scholar
• Vingerhoeds M. H., Storm G., Crommelin D. J. A. Immunoliposomes in vivo. Immunomethods 1994; 4: 259–272
   PubMedGoogle Scholar
• Vingerhoeds M. H., Haisma H. J., Van Muijen M., Van de Rijt R. B. J., Crommelin D. J. A., Storm G. A new application of liposomes in cancer therapy. Immunoliposomes bearing enzymes (immuno-enzymosomes) for site-specific activation of prodrugs. FEBS Lett. 1993; 336: 485–490
   PubMedGoogle Scholar
• Michalek S. M., Childers N. K., Katz J., Denys F. R., Berry A. K., Eldridge J. H., McGhee J. R., Curtiss R. Liposomes as oral adjuvants. Curr. Top. Microbiol. Immunol. 1989; 146: 51–58
   PubMedGoogle Scholar
• Childers N. K., Denys F. R., McGee N. F., Michalek S. M. Ultrastructural study of liposome uptake by M cells of rat Peyer's patch: An oral vaccine system for delivery of purified antigen. Reg. Immunol. 1990; 3: 8–16
   PubMedGoogle Scholar
• Jackson S., Mestecky J., Childers N. K., Michalek S. M. Liposomes containing anti-idiotypic antibodies: An oral vaccine to induce protective secretory immune responses for pathogens of mucosal surfaces. Infect Immun. 1990; 58: 1932–1936
   PubMed Web of Science ®Google Scholar